Twine AJ et al., 2026-07-01: British Journal of Haematology review stating that intravenous methylene blue remains first-line treatment for symptomatic methemoglobinemia, with vitamin C, exchange transfusion and hyperbaric oxygen as alternatives with little evidence.
Management depends on severity, with intravenous methylene blue remaining first-line treatment for symptomatic cases.
Twine AJ et al., 2026-07-01: British Journal of Haematology review stating that intravenous methylene blue remains first-line treatment for symptomatic methemoglobinemia, with vitamin C, exchange transfusion and hyperbaric oxygen as alternatives with little evidence. C3 and C4. Study type: narrative review (Br J Haematol 2026;209:900-910), UK authors (King's College Hospital / NHS affiliations per journal listing; not stated in the abstract). No patients. The authors state they have no conflicts of interest to disclose. Useful for the current-practice statement and for the inherited cytochrome b5 reductase deficiency category it describes. Study type: review.
